Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Calcichew-D3 Forte Double Strength 1000 mg/800 IU Chewable Tablets
Medicines register · Ireland

Calcichew-D3 Forte Double Strength 1000 mg/800 IU Chewable Tablets

Authorisation PA2239/013/003 · CHEPLAPHARM Arzneimittel GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
CHEPLAPHARM Arzneimittel GmbH (all products →)
Active substances
Calcium carbonate, Cholecalciferol concentrate (powder form)
Dosage form
Chewable tablet
Route of administration
Oral use
ATC code
A12AX
First authorised
11/12/2009
Prescription status
Product not subject to medical prescription
Supply
Supply through pharmacies only
Legal basis
Well-established use application (Article 10a of Directive No 2001/83/EC)

Calcium carbonate: supply and approvals

34 authorised products on the HPRA list contain Calcium carbonate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Cholecalciferol concentrate (powder form): supply and approvals

2 authorised products on the HPRA list contain Cholecalciferol concentrate (powder form). Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 16 years (since 11 December 2009). The HPRA list marks it as marketed in Ireland.

Other medicines with Calcium carbonate in Ireland

33 other products on the HPRA list contain Calcium carbonate, from 12 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Acidex Oral Suspension, Sodium Alginate 500mg, Sodium Bicarbonate 267mg, Calcium Carbonate 160mg/10mlPinewood Laboratories LimitedNational authorisation (PA)Marketed
Bisodol Antacid Chewable Tablets Calcium Carbonate 522mg Magnesium Carbonate Light 68mg Sodium Hydrogen Carbonate 64mgDexcel Pharma GmbHNational authorisation (PA)Marketed
Cadelius 600 mg/1000 IU ordispersible tabletItalfarmaco S.A.National authorisation (PA)Marketed
Calcichew 500 mg chewable tabletsCHEPLAPHARM Arzneimittel GmbHNational authorisation (PA)Marketed
Calcichew-D3 Forte 500 mg/400 IU Chewable TabletsCHEPLAPHARM Arzneimittel GmbHNational authorisation (PA)Marketed
Gaviscon Extra Chewable TabletsSodium alginate 250mgSodium bicarbonate 106.5mgCalcium carbonate 187.5mgReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed
Gaviscon Extra Mixed Berries Flavour Chewable Tablets Sodium alginate 250 mg Sodium hydrogen carbonate 106.5 mg Calcium carbonate 187.5 mgReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed
Gaviscon Extra Mixed Berries Oral Suspension Sodium alginate 500 mg/ 10 ml sodium hydrogen carbonate 213 mg/ 10 ml Calcium carbonate 325 mg/ 10 mlReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed
Gaviscon Extra Oral Suspension Sodium alginate 500 mg Sodium bicarbonate 213 mg Calcium carbonate 325 mgReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed
Gaviscon Liquid Peppermint Flavour, Oral Suspension Sodium alginate 500 mg Sodium bicarbonate 267 mg Calcium carbonate 160 mgReckitt Benckiser Ireland LtdNational authorisation (PA)Marketed
Gaviscon Liquid-Aniseed Flavour, Oral Suspension Each 10 ml contains: Sodium alginate 500 mg Sodium bicarbonate 267 mg Calcium carbonate 160 mgReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed
Gaviscon Peppermint Chewable Tablets Sodium alginate 250 mg Sodium hydrogen Carbonate 133.5 mg Calcium Carbonate 80 mgReckitt Benckiser Ireland LimitedNational authorisation (PA)Marketed

All 34 products with Calcium carbonate →

Other medicines with Cholecalciferol concentrate (powder form) in Ireland

1 other product on the HPRA list contains Cholecalciferol concentrate (powder form), from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Calcichew-D3 Forte Double Strength 1000 mg/800 IU Chewable TabletsPCO Manufacturing Ltd.Parallel import (PPA)Not stated

Other substances in ATC group A12AX

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 7 other active substances share the group A12AX with this product:

Calcium (5) · Cholecalciferol (4) · Colecalciferol (3) · Cholecalciferol concentrate (2) · Calcium gluconate (1) · Nicotinic acid (1) · Vitamin d3 (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

CHEPLAPHARM Arzneimittel GmbH holds 74 products on the HPRA list, with 33 different active substances; 44 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.